rational
acut
lung
dysfunct
noninfecti
etiolog
known
idiopath
pneumonia
syndrom
ip
sever
complic
follow
hematopoiet
stem
cell
transplant
hsct
sever
mous
model
recent
develop
determin
underli
caus
ip
cohes
interpret
experiment
data
relationship
find
clinic
research
studi
human
need
better
understand
basi
current
futur
clinic
trial
preventiontreat
ip
object
goal
perform
comprehens
review
preclin
ie
murin
model
clinic
research
ip
method
at
committe
perform
pubm
ovid
search
publish
peerreview
articl
use
keyword
idiopath
pneumonia
syndrom
lung
injuri
pulmonari
complic
bone
marrow
transplant
hematopoiet
stem
cell
transplant
specif
inclus
exclus
criteria
determin
priori
review
measur
main
result
experiment
model
reproduc
variou
pattern
lung
injuri
observ
hsct
identifi
solubl
cellular
inflammatori
mediat
contribut
inflamm
engend
develop
ip
date
preclin
murin
model
ip
spectrum
establish
use
variou
donor
host
strain
combin
use
studi
graftversushost
diseas
gvhd
well
demonstr
cell
depend
ip
develop
model
support
concept
lung
target
immunemedi
attack
hsct
develop
therapeut
strategi
ip
involv
block
tnf
signal
etanercept
current
evalu
clinic
trial
conclus
ip
remain
frequent
fatal
complic
limit
broader
use
allogen
hsct
success
treatment
modal
face
clinic
syndrom
ip
one
categor
diseas
entiti
appropri
tool
although
case
unclassifi
ip
remain
signific
research
effort
result
paradigm
shift
away
identifi
noninfecti
lung
injuri
hsct
sole
idiopath
clinic
syndrom
toward
understand
ip
process
involv
aspect
adapt
innat
immun
respons
importantli
new
laboratori
insight
current
translat
clinic
like
prove
import
develop
futur
strategi
prevent
treat
seriou
disord
acut
pulmonari
dysfunct
frequent
fatal
complic
follow
hematopoiet
stem
cell
transplant
hsct
previous
idiopath
pneumonia
syndrom
ip
defin
describ
subset
patient
sign
symptom
pneumonia
evid
widespread
alveolar
injuri
absenc
lower
respiratori
tract
infect
year
definit
adopt
clinic
practic
use
guid
medic
manag
afflict
patient
howev
outcom
patient
diagnos
ip
remain
unaccept
mortal
rate
high
time
death
follow
diagnosi
short
improv
understand
clinic
spectrum
diseas
mechan
respons
ip
therefor
essenti
physicianscientist
make
progress
treatment
prevent
disord
goal
perform
comprehens
review
preclin
ie
murin
model
clinic
research
ip
at
committe
includ
represent
adult
pediatr
commun
nation
intern
form
invit
base
expertis
care
patient
ip
hsct
andor
expertis
preclin
model
ip
committe
member
perform
pubm
ovid
search
publish
peerreview
articl
use
keyword
idiopath
pneumonia
syndrom
lung
injuri
pulmonari
complic
bone
marrow
transplant
hematopoiet
stem
cell
transplant
committe
member
assign
section
outlin
statement
ask
review
literatur
section
assign
specif
inclus
exclus
criteria
determin
priori
review
committe
member
review
edit
draft
final
version
research
statement
reach
consensu
accuraci
relev
review
current
state
scienc
ip
research
definit
ip
updat
committe
author
statement
shown
tabl
at
defin
ip
idiopath
syndrom
pneumopathi
hsct
evid
widespread
alveolar
injuri
infecti
etiolog
cardiac
dysfunct
acut
renal
failur
iatrogen
fluid
overload
exclud
moreov
ip
classifi
specif
entiti
figur
tabl
base
larg
part
primari
anatom
site
inflamm
dysfunct
intent
better
character
clinic
spectrum
diseas
care
match
subtyp
ip
specif
preclin
model
develop
mimic
ultim
understand
anim
model
prove
valuabl
defin
specif
contributor
pathogenesi
inflamm
evalu
promis
new
therapeut
modal
exampl
result
use
novel
approach
use
reduc
intens
condit
regimen
neutral
tumor
necrosi
factora
encourag
approach
develop
primarili
insight
gain
preclin
studi
purpos
statement
provid
brief
overview
spectrum
noninfecti
lung
injuri
occur
hsct
relat
variou
form
lung
inflamm
definit
ip
provid
comprehens
review
data
gener
use
experiment
anim
model
defin
current
understand
mechan
frequent
fatal
disord
nation
institut
health
workshop
propos
broad
definit
ip
includ
widespread
alveolar
injuri
absenc
activ
lower
respiratori
tract
infect
cardiogen
caus
hsct
shown
tabl
diagnost
criteria
ip
updat
consid
newli
describ
pathogen
determin
bronchoalveolar
lavag
bal
lung
biopsi
practic
sens
diagnosi
ip
base
exclus
infecti
organ
cardiac
dysfunct
acut
renal
failur
iatrogen
fluid
overload
set
pulmonari
dysfunct
hsct
ip
encompass
spectrum
clinic
present
children
adult
thought
result
varieti
lung
insult
includ
toxic
effect
hsct
condit
regimen
immunolog
cellmedi
injuri
inflammatori
cytokin
occult
pulmonari
infect
histor
incid
ip
first
day
allogen
hsct
myeloabl
condit
recent
cumul
incid
ip
allogen
hsct
significantli
lower
follow
nonmyeloabl
condit
convent
fullintens
prepar
regimen
versu
p
establish
howev
pulmonari
toxic
sever
group
result
respiratori
failur
major
patient
find
suggest
intens
hsct
condit
play
import
role
develop
ip
consist
data
gener
mous
model
show
lung
sensit
combin
effect
radiat
alloreact
cell
median
time
onset
ip
initi
report
week
rang
follow
allogen
hsct
recent
studi
indic
earlier
median
time
onset
day
rang
mortal
rate
allogen
hsct
recipi
rang
overal
greater
patient
requir
mechan
ventil
ip
report
follow
autolog
hsct
incid
lower
median
time
onset
gener
longer
rang
two
entiti
differ
sharpli
respect
overal
outcom
inflamm
autolog
set
respond
promptli
corticosteroid
associ
favor
prognosi
wherea
ip
occur
allogen
environ
respond
poorli
standard
therapi
commonli
result
rapid
respiratori
failur
death
major
patient
risk
factor
ip
allogen
hsct
includ
fullintens
condit
total
bodi
irradi
tbi
acut
graftversushost
diseas
gvhd
older
recipi
age
underli
diagnosi
acut
leukemia
myelodysplast
syndrom
md
gvhd
major
caus
morbid
mortal
follow
hsct
caus
donor
cell
reactiv
host
tissu
due
major
minor
human
leukocyt
antigen
hla
dispar
primarili
affect
gut
liver
skin
one
report
show
singl
low
dose
nonmyeloabl
condit
regimen
associ
reduc
incid
ip
remain
fulli
determin
impact
frequent
use
robust
reducedintens
regimen
ip
recent
metaanalysi
investig
found
lung
irradi
dose
cyclophosphamid
dose
addit
busulfan
significantli
associ
develop
interstiti
pneumon
lung
shield
reduc
incid
hsctrelat
ip
although
earlier
studi
identifi
methotrex
mtx
risk
factor
develop
interstiti
pneumonia
studi
distinguish
inflamm
infecti
noninfecti
caus
recent
studi
report
mtx
risk
factor
ip
risk
factor
ip
follow
autolog
hsct
includ
older
patient
age
sever
oral
mucos
tbibas
bischloroethylnitrosourea
bcnu
contain
condit
regimen
chest
irradi
within
week
transplant
femal
sex
underli
diagnosi
solid
tumor
date
impact
stem
cell
sourc
bone
marrow
versu
peripher
blood
versu
umbil
cord
blood
develop
ip
fulli
evalu
thu
expand
use
peripher
blood
umbil
cord
blood
unrel
donor
affect
incid
sever
diseas
remain
elucid
despit
identif
attempt
reduc
risk
factor
overal
mortal
due
ip
remain
unaccept
high
initi
defin
clark
colleagu
clinic
spectrum
ip
encompass
sever
descript
form
pulmonari
dysfunct
one
small
subset
patient
ip
acut
pulmonari
hemorrhag
hemorrhag
alveol
occur
diffus
alveolar
hemorrhag
dah
gener
develop
immedi
posthsct
period
character
progress
short
breath
cough
hypoxemia
without
fever
dah
report
hsct
patient
median
time
onset
day
rang
allogen
recipi
day
rang
autolog
patient
disproportion
higher
incid
dah
posthsct
report
patient
mucopolysaccharidosi
diagnosi
dah
base
progress
bloodier
return
bal
fluid
frank
hemoptysi
rare
presenc
greater
hemosiderinladen
macrophag
bal
fluid
may
give
indic
previou
pulmonari
hemorrhag
howev
find
low
specif
dah
bal
fluid
hemosiderinladen
macrophag
also
common
patient
low
platelet
count
pulmonari
hypertens
mortal
dah
rang
despit
treatment
highdos
corticosteroid
mgkgd
gm
death
usual
result
multiorgan
failur
within
week
diagnosi
majhail
colleagu
recent
compar
patient
dah
infectionassoci
alveolar
hemorrhag
present
similar
clinic
radiograph
find
set
progress
bloodier
bal
fluid
follow
allogen
hsct
alveolar
hemorrhag
infecti
noninfecti
caus
found
relat
distinct
entiti
extrem
poor
outcom
follow
therapi
convent
agent
includ
steroid
periengraft
respiratori
distress
syndrom
perd
repres
anoth
clinic
subset
ip
definit
perd
occur
within
day
engraft
account
ip
case
allogen
hsct
although
clinic
present
perd
convent
allogen
hsct
similar
observ
autolog
patient
allogen
patient
receiv
reducedintens
condit
regimen
celldeplet
stem
cell
graft
lung
dysfunct
respons
corticosteroid
associ
better
prognosi
patient
delay
pulmonari
toxic
syndrom
dpt
also
tradit
fallen
within
definit
ip
incid
dpt
autolog
patient
receiv
chemotherapi
regimen
contain
bcnu
cyclophosphamid
cisplatin
median
time
onset
dpt
day
rang
treatment
corticosteroid
mgkgd
lead
resolut
case
highdos
inhal
corticosteroid
prophylaxi
may
also
benefici
patient
implic
dpt
directli
relat
specif
hsct
condit
regimen
suggest
entiti
technic
categor
ip
per
se
potenti
etiolog
ip
includ
direct
toxic
effect
hsct
condit
regimen
occult
pulmonari
infect
releas
inflammatori
cytokin
implic
form
pulmonari
injuri
note
dose
intens
hsct
condit
may
affect
frequenc
ip
specif
combin
chemotherapeut
agent
predispos
pulmonari
dysfunct
subset
hsct
recipi
histor
approxim
one
half
pneumonia
seen
hsct
secondari
infect
judici
use
broadspectrum
antimicrobi
agent
tip
balanc
noninfecti
caus
togeth
broadspectrum
prophylaxi
develop
applic
advanc
diagnost
techniqu
includ
immunohistochem
stain
indirect
fluoresc
antibodi
test
polymeras
chain
reaction
pcr
significantli
reduc
incid
pneumon
cmv
pneumocysti
jirovecii
enhanc
util
bronchoalveolar
lavag
rule
presenc
opportunist
pathogen
particular
import
given
impact
make
correct
diagnosi
approach
subsequ
medic
therapi
discuss
later
manag
ip
enhanc
immunosuppress
infect
antimicrobi
therapi
quit
diverg
associ
ip
sever
gvhd
report
sever
larg
seri
suggest
immunolog
factor
may
also
oper
develop
lung
injuri
acut
gvhd
often
preced
ip
suggest
possibl
causal
relationship
two
disord
although
ip
also
occur
sign
symptom
gvhd
limit
absent
consist
associ
lung
injuri
gvhd
experiment
model
also
support
etiolog
despit
aforement
clinic
associ
lung
tradit
recogn
classic
gvhd
target
organ
specif
role
alloreact
donor
lymphocyt
pathogenesi
ip
remain
topic
consider
debat
epitheli
apoptosi
usual
attribut
cellmedi
injuri
consid
pathognomon
acut
gvhd
although
identifi
lung
patient
ip
epitheli
apoptosi
consist
observ
allogen
hsct
recipi
pulmonari
dysfunct
histolog
spectrum
pulmonari
gvhd
recent
describ
rang
diffus
alveolar
injuri
earli
hsct
cicatr
bronchiol
obliteran
late
irrevers
form
lung
injuri
bronchitisbronchiol
interstiti
pneumon
common
find
includ
lymphocyt
infiltr
around
bronchial
structur
along
mononuclear
inflamm
perivascular
zone
alveolar
septa
bronchiol
obliteran
syndrom
bo
also
call
oblit
bronchiol
ob
bronchiol
obliteran
organ
pneumonia
boop
call
cryptogen
organ
pneumonia
cop
two
lateonset
noninfecti
lung
complic
associ
allohsct
presenc
gvhd
incid
bo
vari
approxim
almost
time
onset
rang
month
almost
year
hsct
commonli
month
time
transplant
incid
cop
boop
much
lower
median
onset
month
transplant
gener
copboop
treat
corticosteroid
major
case
bo
resist
treatment
review
refer
histopatholog
gener
consid
gold
standard
diagnost
approach
clinic
disord
diagnosi
ip
rare
made
confirm
tissu
biopsi
given
signific
mortal
risk
open
lung
biopsi
earli
transplant
period
lack
pathognomon
histolog
pattern
ip
heterogen
pulmonari
patholog
allogen
hsct
complic
nonspecif
lung
injuri
chang
may
occur
mechan
ventil
limit
qualiti
quantiti
transbronchi
lung
biopsi
specimen
obtain
hsct
recipi
unfortun
categor
patient
ip
base
upon
descript
clinic
terminolog
equal
unreward
help
new
improv
diagnost
techniqu
immunohistochemistri
radiolog
microbiolog
propos
categor
diseas
entiti
fall
umbrella
ip
primari
anatom
site
cellular
damag
includ
interstiti
tissu
vascular
endothelium
airway
epithelium
tabl
case
may
remain
unclassifi
approach
may
focu
futur
line
investig
specif
pathway
tissu
injuri
therebi
foster
develop
therapeut
intervent
tailor
distinct
subtyp
diseas
end
better
defin
pathogenesi
ip
sever
murin
model
develop
use
extens
investig
immunolog
mechan
injuri
contribut
damag
vascular
endothelium
well
alveolar
bronchiolar
epithelium
context
wealth
experiment
data
markedli
improv
understand
pathophysiolog
process
regul
ip
reveal
cellular
effector
varieti
solubl
effector
contribut
inflamm
engend
diseas
progress
sever
murin
model
lung
injuri
hsct
establish
use
varieti
strain
combin
condit
regimen
tabl
includ
lethal
irradi
major
histocompat
complex
mhc
match
multipl
minor
antigen
mismatch
complet
mhc
mismatch
model
without
cyclophosphamid
lethal
irradi
haploident
parent
model
mhc
class
mismatch
mhc
class
ii
mismatch
syngen
hsct
model
use
highdos
chemotherapi
model
use
mhc
class
class
ii
mismatch
donorrecipi
strain
combin
best
reproduc
acut
earlyonset
ip
model
pulmonari
toxic
caus
influx
host
monocyt
donor
cell
lung
lethal
irradi
mice
within
first
week
hsct
intensifi
prehsct
condit
cyclophosphamid
acceler
develop
ip
consist
human
data
classif
standpoint
see
figur
lung
injuri
character
injur
type
ii
alveolar
atii
epitheli
cell
injur
endotheli
cell
increas
frequenc
cytotox
lymphocyt
cell
express
famili
costimulatori
ligand
alveolar
interstiti
space
lung
dysfunct
acut
model
reflect
interstiti
alveolar
damag
present
reduc
specif
complianc
decreas
total
lung
capac
increas
wet
dri
lung
weight
bal
fluid
mice
ip
contain
elev
level
solubl
mediat
includ
cytokin
well
nitrit
lactat
dehydrogenas
total
protein
indic
lung
inflamm
pulmonari
endotheli
damag
leak
similar
find
decreas
complianc
oxid
stress
seen
earlyonset
syngen
ip
model
dpt
mice
condit
highdos
chemotherapi
alon
murin
system
wherein
donor
host
differ
multipl
minor
hc
antigen
isol
mhc
class
class
ii
loci
close
reflect
condit
typic
seen
definit
abbrevi
aip
acut
interstiti
pneumon
ard
acut
respiratori
distress
syndrom
bcnu
bischloroethylnitrosourea
boop
bronchiol
obliteran
organ
pneumonia
bo
bronchiol
obliteran
syndrom
dah
diffus
alveolar
hemorrhag
dpt
delay
pulmonari
toxic
syndrom
ep
eosinophil
pneumonia
pah
pulmonari
arteri
hypertens
pap
pulmonari
alveolar
proteinosi
pct
pulmonari
cytolyt
thrombi
perd
periengraft
respiratori
distress
syndrom
ptld
posttranspl
lymphoprolif
diseas
pvod
pulmonari
venoocclus
diseas
trali
transfusionrel
acut
lung
injuri
human
hsct
specif
model
ip
develop
first
week
transplant
character
leukocyt
infiltr
lung
observ
lung
biopsi
regardless
strain
combin
two
primari
reproduc
abnorm
appar
experiment
model
dens
mononuclear
cell
infiltr
around
pulmonari
vessel
bronchiol
acut
pneumon
involv
interstitium
alveolar
space
repres
three
anatom
categori
outlin
figur
measur
alter
pulmonari
function
associ
lung
histopatholog
demonstr
observ
lung
inflamm
physiolog
relev
alveolar
infiltr
compos
macrophag
lymphocyt
epitheli
cell
scatter
polymorphonuclear
cell
within
fibrin
matrix
wherea
perilumin
around
vascular
bronchial
structur
infiltr
compos
primarili
activ
donor
cell
moreov
signific
pulmonari
endotheli
apoptosi
dysfunct
identifi
context
endotheli
injuri
coincid
onset
pulmonari
patholog
associ
elev
bal
fluid
tnfa
level
extent
injuri
directli
correl
sever
lung
inflamm
ip
progress
despit
presenc
endotheli
damag
diffus
alveolar
hemorrhag
regularli
seen
preclin
ip
model
except
mice
challeng
lipopolysaccharid
lp
scenario
hemorrhag
observ
mice
advanc
gvhd
associ
larg
increas
bal
fluid
level
neutrophil
tnfa
lp
collect
signific
bodi
experiment
data
suggest
mous
model
ip
reproduc
mani
histolog
function
chang
observ
human
diseas
end
sever
investig
use
model
uncov
pathway
inflamm
may
oper
human
diseas
attempt
identifi
opportun
effect
treat
prevent
complic
mix
inflammatori
alveolar
infiltr
found
mice
ip
associ
increas
tnfa
lung
tissu
bal
fluid
causal
role
tnfa
develop
ip
establish
neutral
cytokin
experiment
hsct
model
administr
solubl
dimer
tnfbind
protein
rhtnfr
fc
amgen
corp
thousand
oak
ca
week
week
hsct
reduc
progress
lung
injuri
time
period
use
mutant
mice
defici
tnfa
shown
lung
injuri
allogen
hsct
depend
upon
donor
rather
hostderiv
tnfa
cytokin
product
donor
accessori
cell
macrophagemonocyt
cell
significantli
contribut
toxic
tnfa
like
contribut
develop
ip
direct
indirect
mechan
tnfa
increas
mhc
complex
express
modul
leukocyt
migrat
facilit
cellmedi
cytotox
cytotox
recent
shown
tnfa
contribut
pulmonari
vascular
endotheli
cell
apoptosi
accompani
lung
inflamm
develop
ip
moreov
donorderiv
tnfa
serv
facilit
effector
lung
injuri
tnfa
secret
donor
cell
regul
chemokin
milieu
lung
within
first
week
hsct
directli
contribut
subsequ
recruit
monocytesmacrophag
lung
injuri
progress
action
tnfa
mediat
two
receptor
type
receptor
tnfri
type
ii
receptor
tnfrii
two
receptor
coexpress
almost
everi
cell
bodi
contrast
constitut
express
tnfri
express
tnfrii
strongli
modul
variou
cytokin
inflammatori
stimuli
like
lp
tnfri
gener
regard
domin
receptor
tnfa
biolog
highaffin
receptor
solubl
tnfa
stnfa
mediat
mani
proinflammatori
effect
cytokin
stnfa
memtnfa
transmembran
form
tnfa
abl
activ
tnfri
tnfrii
fulli
activ
memtnfa
tnfrii
contribut
cytocid
effect
tnfa
signal
also
regul
access
cytokin
tnfri
therebi
enhanc
tnfri
signal
role
tnfri
induct
gvhd
earli
allohsct
previous
describ
stnfa
product
directli
relat
toxic
pretranspl
condit
proinflammatori
respons
accompani
donor
cell
activ
expans
earli
allohsct
demonstr
absenc
tnfri
allohsct
recipi
result
improv
earli
posthsct
surviv
associ
decreas
pulmonari
edema
improv
lung
complianc
day
hsct
howev
cellular
infiltr
lung
bal
fluid
level
proinflammatori
cytokin
chemokin
actual
higher
bal
fluid
tnfri
hsct
recipi
compar
tnfri
control
find
consist
report
ip
induc
across
minor
h
antigen
isol
mhc
class
differ
wherein
interact
tnfrii
tnfa
contribut
leukocyt
infiltr
pulmonari
inflamm
studi
reduct
lung
injuri
observ
tnfrii
allohsct
recipi
directli
mirror
favor
outcom
observ
tnfa
mice
use
hsct
donor
increas
neutrophil
tnfa
lung
allogen
hsct
recipi
without
evid
infect
suggest
host
floraderiv
lp
might
play
import
role
ip
pathophysiolog
lp
involv
initi
innat
immun
respons
potent
enhanc
inflammatori
cytokin
releas
nonhsct
experiment
model
intratrach
administr
lp
elicit
sever
acut
inflammatori
respons
lung
anim
recent
work
also
demonstr
lp
import
effector
molecul
develop
acut
gvhd
transloc
lp
across
gut
mucosa
damag
earli
posttranspl
period
provid
access
system
circul
stimul
leukocyt
releas
inflammatori
mediat
subsequ
contribut
gvhd
target
organ
damag
dysfunct
lp
level
elev
bal
fluid
mice
ip
lp
stimul
releas
inflammatori
cytokin
directli
contribut
lung
damag
intraven
lp
inject
week
allogen
hsct
significantli
amplifi
lung
injuri
amplif
seen
mice
advanc
gvhd
associ
larg
increas
bal
fluid
level
tnfa
lp
develop
alveolar
hemorrhag
collect
data
demonstr
inflammatori
mediat
tnfa
lp
contribut
experiment
ip
moreov
support
hypothesi
gutliverlung
axi
inflamm
ip
pathophysiolog
process
ultim
result
larg
amount
endotoxin
andor
tnfa
pulmonari
circul
may
contribut
develop
lung
injuri
set
hypothesi
consist
observ
serum
bal
fluid
tnfa
level
increas
patient
ip
clinic
linkag
hepat
dysfunct
lung
injuri
hsct
also
suggest
associ
venoocclus
diseas
vod
ip
hepat
failur
death
ip
furthermor
evid
cytokin
activ
lp
amplif
observ
bal
fluid
patient
acut
respiratori
distress
syndrom
ard
demonstr
patient
ip
allogen
hsct
increas
pulmonari
vascular
permeabl
increas
bal
fluid
level
tnfa
lpsbind
protein
lbp
solubl
also
observ
patient
incomplet
protect
provid
abrog
effect
tnfa
hsct
variou
strategi
consist
report
mani
group
suggest
inflammatori
cellular
mechan
fasfasl
pathway
mediat
acut
gvhd
may
also
contribut
develop
ip
exampl
tgfb
nitrat
speci
includ
nitric
oxid
peroxynitrit
also
implic
develop
ip
particularli
cyclophosphamid
includ
condit
regimen
proinflammatori
event
hsct
frequent
accompani
enhanc
product
reactiv
oxygen
speci
ro
reactiv
nitrogen
speci
rn
concomit
increas
oxid
nitros
stress
exposur
radiochemotherapi
increas
oxid
stress
deplet
antioxid
defens
includ
reduc
glutathion
major
antioxid
epitheli
line
fluid
lung
observ
confirm
murin
ip
model
allogen
autolog
hsct
hsct
also
associ
state
iron
excess
free
iron
becom
avail
catalyz
convers
ro
intermedi
highli
toxic
free
radic
hydroxyl
radic
lung
particularli
sensit
oxygenrich
environ
exhal
nitric
oxid
also
increas
lower
respiratori
tract
hsct
potenti
sourc
nitric
oxid
chemotherapyinduc
inflamm
lung
epithelium
lunginfiltr
inflammatori
cell
simultan
gener
larg
amount
nitric
oxid
rapidli
react
superoxid
form
peroxynitrit
potent
oxid
nitrat
speci
oxidantantioxid
imbal
may
directli
caus
cellular
injuri
may
trigger
multipl
inflammatori
signal
transduct
pathway
direct
evid
oxid
stress
play
distinct
role
develop
ip
injuri
human
lack
howev
experiment
model
indic
recipi
mice
given
highdos
chemotherapi
treat
nacetylcystein
exhibit
substanti
less
lung
injuri
compar
mice
receiv
highdos
chemotherapi
without
nacetylcystein
like
mechan
protect
effect
nacetylcystein
replenish
andor
preserv
glutathion
redox
potenti
although
direct
scaveng
reactiv
speci
nacetylcystein
may
also
contribut
furthermor
overexpress
extracellular
superoxid
dismutas
ecsod
major
extracellular
antioxid
enzym
lung
confer
protect
radiationinduc
acut
lung
injuri
togeth
data
suggest
amelior
oxid
stress
may
reduc
develop
sever
ip
injuri
howev
human
studi
use
lungtarget
antioxid
approach
lack
question
concern
potenti
antioxid
affect
efficaci
chemotherapi
need
address
pulmonari
surfact
produc
alveolar
type
ii
cell
compos
complex
mixtur
lipid
least
four
surfact
protein
sp
name
order
discoveri
presenc
surfact
bloodga
interfac
essenti
surviv
airbreath
mammal
reduc
surfac
tension
surfact
decreas
work
breath
allow
alveoli
remain
open
end
expir
keep
alveoli
dri
addit
surfact
particularli
spa
spd
major
role
host
defens
regul
immun
respons
lung
surfact
dysfunct
caus
decreas
synthesi
alveolar
type
ii
cell
inhibit
function
extravas
serum
protein
degrad
lipas
oxid
like
contribut
ip
clinic
pictur
hypoxemia
progress
dyspnea
pulmonari
edema
limit
number
experiment
human
studi
evalu
role
surfact
lung
dysfunct
follow
hsct
model
sever
ip
follow
lethal
irradi
mice
lack
spa
spd
exhibit
exagger
allogen
celldepend
inflamm
associ
enhanc
marker
lung
injuri
furthermor
transtrach
instil
human
spa
attenu
manifest
ip
mice
human
pretranspl
serum
level
spd
identifi
risk
factor
develop
ip
bronchiol
obliteran
allogen
hsct
investig
specul
certain
polymorph
human
spd
gene
caus
subnorm
level
spd
alveoli
serum
low
level
spd
may
predispos
individu
enhanc
inflammatori
respons
exposur
condit
regimen
allogen
immun
respons
contribut
develop
ip
investig
shown
serum
level
spd
valuabl
biomark
acut
lung
injuri
predict
outcom
similarli
serum
spd
may
also
use
test
follow
clinic
cours
ip
extent
relationship
first
need
establish
clinic
trial
studi
requir
determin
specif
role
surfact
protein
ip
injuri
despit
overwhelm
success
prematur
infant
result
surfact
replac
trial
acut
lung
injuri
variabl
phase
iii
studi
underway
determin
efficaci
novel
surfact
prepar
close
resembl
natur
surfact
investig
reveal
benefici
effect
mortal
trial
optim
surfact
prepar
dose
time
administr
need
perform
role
alloreact
donor
cell
pathogenesi
ip
topic
consider
debat
particularli
sinc
lung
consid
classic
target
organ
acut
gvhd
import
lymphocyt
lung
injuri
experiment
hsct
howev
shown
sever
group
donor
cell
critic
earli
proinflammatori
event
associ
lung
injuri
develop
within
first
week
hsct
across
mhc
antigen
wherea
minor
h
antigen
mismatch
system
donor
lymphocyt
continu
respond
host
antigen
contribut
physiolog
signific
lung
injuri
later
time
point
furthermor
infus
donor
cell
clone
recogn
allel
differ
cell
surfac
express
molecul
nonirradi
recipi
result
rapidli
progress
pulmonari
vascul
within
day
inject
origin
function
capac
cell
infiltr
lung
examin
use
differ
cell
vb
repertoir
donor
recipi
flow
cytometr
analysi
demonstr
tcrab
cell
found
lung
week
allogen
hsct
donor
origin
donor
cell
recultur
irradi
host
antigenpres
cell
apc
prolifer
vigor
produc
signific
amount
ifng
use
model
ip
wherein
donor
host
differ
class
mhc
antigen
shown
donorderiv
cell
express
ifng
present
lung
allohsct
recipi
earli
day
influx
cell
correl
elev
protein
level
two
princip
ligand
see
herald
onset
signific
pulmonari
inflamm
robust
infiltr
occur
reproduc
model
ifng
receptorligand
interact
complet
intact
recent
studi
paradox
show
pulmonari
inflamm
acceler
ifng
signal
absent
regulatori
effect
entir
mediat
pulmonari
parenchyma
result
later
independ
confirm
extend
show
ifng
neg
regul
expans
cell
lung
ip
furthermor
recent
demonstr
vitro
differenti
cell
mediat
sever
pulmonari
patholog
mous
model
gvhd
role
cell
tissu
inflamm
current
area
intens
studi
experiment
data
suggest
donorderiv
cell
effector
home
lung
earli
hsct
contribut
physiolog
signific
tissu
injuri
precis
cytolyt
target
cell
process
activ
host
antigen
remain
unresolv
process
like
complex
involv
interact
pulmonari
parenchym
cell
apc
likewis
cell
respons
activ
cell
effector
ultim
recruit
lung
specif
locat
cellular
activ
event
also
remain
enigmat
donor
cell
contribut
ip
may
initi
encount
host
apc
resid
distant
secondari
lymphoid
tissu
subsequ
specif
recruit
lung
follow
upregul
chemotact
receptor
includ
also
possibl
donor
cell
activ
pulmonari
microenviron
pulmonari
dendrit
cell
dc
significantli
effici
alveolar
macrophag
antigen
present
function
domin
apc
lung
pulmonari
dc
locat
pulmonari
interstitium
bronchial
epithelium
submucosa
sole
sourc
mhc
class
ii
express
within
epitheli
line
airway
steadyst
condit
antigenpres
capac
pulmonari
dc
regul
am
exist
close
proxim
dc
airway
lung
parenchyma
addit
am
vitro
dc
cultur
enhanc
regulatori
effect
wherea
deplet
am
vivo
enhanc
apc
function
freshli
isol
dc
pulmonari
dc
play
critic
role
initi
regul
immun
respons
lung
recent
data
suggest
import
acut
chronic
reject
lung
allograft
possibl
radioresist
host
dc
persist
longer
lung
organ
allow
sustain
present
host
antigen
organ
activ
donor
cell
caus
progress
lung
injuri
might
therefor
remain
within
pulmonari
microvascular
circul
persist
host
dc
serv
continu
site
alloantigen
present
role
donor
accessori
cell
popul
monocyt
macrophag
neutrophil
pathophysiolog
ip
examin
use
hsct
donor
differ
respons
lp
virtu
genet
mutat
tolllik
receptor
tlr
gene
absenc
key
cell
surfac
receptor
lpslbp
complex
case
signific
decreas
lung
injuri
observ
recipi
lp
resist
donor
cell
compar
wildtyp
lpssensit
donor
cell
result
obtain
use
donor
consist
report
monocyt
recruit
inflam
lung
upregul
express
show
enhanc
sensit
lp
stimul
clinic
evid
cytokin
activ
compon
lpsactiv
system
includ
lbp
solubl
present
bal
fluid
hsct
patient
ip
polymorphonuclear
cell
major
compon
bal
fluid
anim
ip
mous
ip
model
bal
fluid
neutrophilia
promin
week
hsct
associ
increas
bal
fluid
level
tnfa
lp
neutral
tnfa
rhtnfr
fc
time
interv
prevent
influx
neutrophil
reduc
progress
lung
injuri
dysfunct
administr
rhtnfr
fc
follow
lp
challeng
complet
abrog
recruit
neutrophil
lung
prevent
damag
includ
hemorrhag
underscor
relationship
neutrophil
tnfa
lp
set
neutrophil
product
elastas
myeloperoxidas
metalloproteinas
oxid
abund
bal
fluid
patient
ard
believ
contribut
endotheli
epitheli
damag
occur
set
neutrophil
like
play
role
patient
ip
well
appear
bloodstream
often
tempor
associ
onset
lung
inflamm
cellular
effector
play
signific
role
develop
ip
molecular
mechan
leukocyt
traffic
lung
caus
damag
yet
fulli
elucid
persist
elicit
leukocyt
lung
allogen
hsct
requir
intercellular
commun
infiltr
leukocyt
endothelium
parenchym
cell
compon
extracellular
matrix
chemokin
virtu
specif
cell
surfac
receptor
express
select
mediat
local
recruitmentactiv
distinct
leukocyt
allow
migrat
across
endothelium
beyond
vascular
compart
along
establish
chemotact
gradient
chemokin
superfamili
divid
four
subfamili
c
cc
cxc
cx
c
base
presenc
conserv
cystein
residu
nh
terminu
cxc
chemokin
subdivid
basi
presenc
absenc
sequenc
glutam
acidleucinearginin
elr
near
nh
termin
elr
cxc
chemokin
neutrophil
chemoattract
angiogen
properti
interferoninduc
elr
cxc
chemokin
chemoattract
lymphocyt
angiostat
properti
cc
chemokin
predominantli
recruit
mononuclear
cell
c
cx
c
subfamili
predominantli
attract
lymphocyt
chemokin
action
mediat
seventransmembranespan
g
proteincoupl
receptor
cc
chemokin
role
ip
evalu
use
lethal
irradi
haploident
murin
model
investig
found
increas
express
lung
undergo
ip
parallel
recruit
leukocyt
cellular
express
importantli
donor
cell
use
reduct
lung
infiltr
mononuclear
cell
result
attenu
ip
convers
aggress
lethal
irradi
mhc
dispar
ip
model
use
recipi
result
similar
degre
host
monocyt
donor
cell
recruit
ip
compar
wild
type
recipi
collect
studi
demonstr
biolog
import
model
ip
evolv
time
cours
two
four
week
reflect
sequenti
recruit
express
donor
cell
compar
aggress
form
ip
host
apc
chemokin
act
parallelseri
may
play
import
role
potent
chemoattract
mononuclear
cell
express
use
lethal
irradi
mhc
dispar
murin
model
ip
describ
investig
found
elev
lung
level
surprisingli
donor
cell
use
model
increas
sequestr
cell
lung
result
increas
ip
sever
mechanist
recipi
donor
cell
found
increas
type
cytokin
profil
demonstr
chemokin
role
modul
type
ii
immun
respons
ip
similar
rant
also
recruit
mononuclear
cell
express
howev
donor
cell
use
lethal
irradi
haploident
murin
model
ip
attenu
ip
collect
studi
demonstr
import
specif
cc
chemokin
mediat
inflammatori
respons
engend
lung
pathogenesi
ip
use
lethal
irradi
haploident
murin
model
ip
investig
also
found
augment
lung
express
itac
parallel
mononuclear
cell
recruit
ip
investig
use
irradi
murin
mhc
class
mismatch
model
ip
found
elev
level
mig
correl
recruit
cell
lung
day
hsct
vivo
neutral
hsct
use
donor
leukocyt
led
reduct
lung
infiltr
cell
attenu
ip
demonstr
import
biolog
model
ip
lethal
irradi
allogen
mous
model
use
icam
recipi
aspect
pathogenesi
ip
found
distinct
develop
gvhd
tradit
target
organ
influx
cell
macrophag
neutrophil
lung
product
inflammatori
cytokin
dramat
decreas
icam
allogen
hsct
recipi
compar
wildtyp
control
contrast
system
level
cytokin
unaffect
gvhdinduc
lesion
liver
colon
least
sever
wildtyp
recipi
furthermor
gvhdmediat
mortal
acceler
recipi
dose
allogen
spleen
cell
otherwis
uniform
lethal
impli
play
critic
role
gener
ip
may
discern
element
segreg
ip
gvhd
injuri
attempt
block
adhes
molecul
interact
human
undergo
hsct
shown
mix
result
one
seri
patient
leukocyt
adhes
defici
lad
given
allogen
hsct
combin
antileukocyt
functionassoci
antigen
lfa
treatment
achiev
reason
engraft
major
patient
develop
gvhd
phase
ii
studi
highrisk
graft
failur
gvhd
prevent
patient
given
howev
patient
tend
longlast
immunodefici
infecti
complic
pulmonari
endotheli
epitheli
cell
express
mhc
class
mhc
class
ii
minor
histocompat
h
antigen
express
molecul
vascular
endothelium
enhanc
tnfa
ifng
conceiv
therefor
pulmonari
parenchym
cell
serv
target
direct
cellmedi
damag
definit
proof
yet
shown
allogeneicmedi
endotheli
damag
demonstr
transfer
allogen
lymphocyt
immunedefici
mice
endotheli
cell
ec
injuri
observ
allogen
hsct
implic
direct
contributor
develop
sever
complic
includ
gvhd
vod
thrombot
microangiopathi
clinic
experiment
ip
associ
evid
ec
injuri
leak
demonstr
pulmonari
edema
enhanc
total
protein
level
bal
fluid
increas
wettodri
lung
weight
ratio
moreov
leukocyt
infiltr
ip
accompani
signific
apoptosi
pulmonari
vascular
endothelium
ec
apoptosi
coincid
onset
pulmonari
patholog
associ
elev
bal
fluid
tnfa
level
accompani
evid
ec
activ
measur
enhanc
mrna
express
adhes
molecul
administr
solubl
tnfabind
protein
rhtnfr
fc
week
week
allogen
hsct
significantli
reduc
ec
apoptosi
lung
histopatholog
observ
mice
contrast
epitheli
apoptosi
gener
ascrib
cellmedi
injuri
consid
pathognomon
acut
gvhd
target
tissu
consist
observ
allogen
hsct
recipi
lung
injuri
uniqu
aspect
epitheli
anatomi
lung
may
help
explain
discrep
sinc
stratif
layer
pulmonari
epitheli
cell
skin
intestin
identif
epitheli
cell
apoptosi
histolog
criteria
challeng
experiment
studi
howev
provid
evid
epitheli
injuri
ip
panoskaltsismortari
cowork
demonstr
ip
associ
injur
alveolar
type
ii
cell
increas
frequenc
cytotox
lymphocyt
model
earlyonset
ip
group
later
show
keratinocyt
growth
factor
mediat
epitheli
cell
prolifer
growth
factor
type
ii
pneumocyt
diminish
ip
injuri
dampen
immun
respons
chemoradiotherapi
acceler
repair
damag
tissu
specif
alveolar
type
ii
epitheli
cell
shown
murin
model
oblit
bronchiol
hsct
bronchiolar
epitheli
cell
express
mhc
class
ii
surround
cell
express
granzym
b
prior
occlus
airway
keratinocyt
growth
factor
kgf
mediat
epitheli
cell
prolifer
mesenchymalepitheli
interact
growth
factor
type
ii
pneumocyt
kgf
protect
chemotherapyand
radiationinduc
injuri
variou
rodent
model
mous
hsct
model
vivo
administr
exogen
kgf
complet
prior
condit
amelior
gvhd
investig
target
pulmonari
injuri
kgf
protect
lethal
model
radiat
hyperoxia
acid
bleomycininduc
lung
injuri
rat
possibl
facilit
repair
dna
damag
alveolar
epitheli
cell
furthermor
kgf
induc
increas
lung
surfact
level
potenti
alveolar
fluid
clearanc
increas
na
katpas
activ
decreas
hyperoxiainduc
apoptosi
alveolar
type
ii
cell
may
detoxifi
reactiv
oxygen
speci
gener
injur
cell
review
refer
acut
earlyonset
ip
mous
model
kgf
diminish
ip
injuri
dampen
immun
respons
chemoradiotherapi
acceler
repair
damag
tissu
specif
alveolar
type
ii
atii
cell
furthermor
associ
abil
rhukgf
upregul
express
spa
limit
ip
injuri
recipi
allogen
hsct
observ
establish
causal
relationship
rhukgf
administ
subcutan
consecut
day
irradi
spasuffici
spa
spadefici
spa
mice
given
inflammationinduc
allogen
cell
time
hsct
rhukgf
fail
suppress
high
level
tnfa
ifng
nitric
oxid
contain
bal
fluid
collect
day
hsct
spa
mice
compar
wildtyp
spa
mice
kgftreat
mice
also
significantli
lower
level
serum
tnfa
nonkgftreat
counterpart
find
consist
complet
mhc
mismatch
parent
mous
hsct
model
associ
lower
tnfa
lp
level
less
sever
manifest
gvhd
lung
injuri
posthsct
consist
hypothesi
tnfa
lp
contribut
ip
injuri
approach
hsct
patient
acut
pulmonari
dysfunct
complex
requir
varieti
diagnost
test
possibl
consult
expert
field
pulmonolog
cardiolog
nephrolog
radiolog
critic
care
medicin
symptom
respiratori
distress
progress
rapidli
establish
time
coordin
care
essenti
optim
outcom
addit
sever
diagnost
challeng
address
set
pulmonari
nonpulmonari
caus
respiratori
compromis
possibl
determin
sever
respiratori
dysfunct
includ
assess
need
supplement
oxygen
support
overal
fluid
balanc
renal
function
cardiac
output
follow
radiograph
imag
gener
initi
chest
xray
ct
scan
identifi
presenc
lobar
multilobar
diffus
pulmonari
infiltr
find
may
impact
decisionmak
process
nondiagnost
absenc
obviou
leftsid
heart
failur
iatrogen
fluid
overload
bronchoscopi
bal
strongli
consid
multilobar
diffus
infiltr
present
bal
fluid
sampl
sent
varieti
diagnost
test
determin
presenc
communityacquir
hospitalacquir
otherwis
opportunist
infect
accept
mani
larg
transplant
center
need
complet
bal
hsct
recipi
signific
respiratori
compromis
remain
matter
debat
particularli
patient
critic
ill
recent
yanik
colleagu
report
result
bronchoscopi
procedur
complet
patient
receiv
hsct
univers
michigan
procedur
complic
note
case
includ
hypoxemia
bleed
hypotens
importantli
patient
breath
spontan
bronchoscopi
requir
endotrach
intub
mechan
ventil
within
initi
hour
procedur
bal
specimen
collect
first
day
hsct
posit
infect
number
increas
day
henc
although
major
hsct
patient
requir
bal
within
first
day
may
ip
signific
number
individu
evid
infect
end
bal
data
result
chang
medic
manag
approxim
case
modif
antimicrobi
therapi
half
note
one
recipi
allogen
hsct
evid
pneumocysti
underscor
effect
antimicrobi
prophylaxi
scope
subsequ
infecti
complic
sinc
medic
manag
ip
immunosuppress
infect
antimicrobi
therapi
rather
diverg
make
appropri
diagnosi
signific
merit
current
standard
treatment
strategi
ip
includ
support
care
measur
conjunct
broadspectrum
antimicrobi
agent
intraven
corticosteroid
unfortun
respons
standard
therapi
limit
mortal
patient
diagnos
ip
remain
unaccept
high
respons
corticosteroid
therapi
shown
mix
limit
efficaci
one
hand
highdos
corticosteroid
therapi
mgkgd
methylprednisolon
equival
shown
improv
outcom
compar
lower
dose
corticosteroid
mgkgd
patient
diagnos
ip
hand
presenc
dah
form
ip
highdos
steroid
may
increas
efficaci
improv
mortal
versu
addit
aminocapro
acid
may
improv
outcom
howev
overal
respons
steroid
patient
present
dah
remain
disappoint
advanc
support
care
includ
earli
institut
continu
venoven
hemofiltr
may
help
improv
surviv
patient
prospect
studi
address
treatment
ip
includ
specif
use
steroid
lack
literatur
insight
gener
preclin
model
ip
suggest
neutral
tnfa
may
use
therapeut
strategi
ip
recent
translat
research
effort
etanercept
given
subcutan
dose
mgkg
twice
weekli
maximum
eight
dose
combin
system
steroid
empir
antimicrobi
therapi
total
patient
ip
patient
evid
system
inflamm
pulmonari
vascular
dysfunct
prior
enrol
studi
therapi
well
toler
overal
ten
patient
abl
complet
withdraw
supplement
oxygen
support
within
day
therapi
surviv
day
day
first
etanercept
dose
significantli
improv
base
encourag
result
larger
phase
ii
pediatr
phase
iii
adult
trial
ongo
within
bone
marrow
transplant
clinic
trial
network
phase
iii
children
oncolog
group
phase
ii
consist
anim
studi
patient
ip
respond
etanercept
therapi
categor
patient
ip
base
upon
presum
anatom
site
primari
injuri
exploit
mechanist
insight
gain
laboratori
describ
may
avail
use
promis
noncrossreact
agent
treatment
ip
conceiv
approach
maintain
ec
integr
may
effect
prevent
treat
ip
administr
molecul
function
surviv
factor
ec
success
prevent
endotheli
damag
mortal
septic
shock
radiat
injuri
specif
kgf
shown
efficaci
reduc
epitheli
damag
sever
acut
gvhd
mice
human
experiment
ip
allogen
hsct
well
protect
pulmonari
endothelium
oxygeninduc
injuri
similarli
futur
studi
examin
role
surfact
replac
therapi
perhap
combin
etanercept
might
prove
use
overcom
effect
epitheli
injuri
dysfunct
ventil
oxygen
final
role
specif
chemokin
receptor
ligand
interact
develop
experiment
ip
suggest
protein
may
also
oper
clinic
set
well
particularli
diseas
onset
later
inflamm
cellular
rather
solubl
effector
predomin
sinc
ip
develop
progress
respiratori
failur
despit
signific
system
immunosuppress
possibl
novel
strategi
direct
toward
inhibit
pathway
leukocyt
recruit
lung
may
serv
futur
adjunct
standard
therapi
intend
prevent
treat
seriou
complic
ip
remain
frequent
sever
complic
allogen
hsct
despit
signific
advanc
critic
care
medicin
mortal
rate
remain
unaccept
high
standard
therapi
although
lung
injuri
occasion
occur
autolog
transplant
allogen
set
significantli
exacerb
toxic
increas
likelihood
treatment
failur
recent
effort
prehsct
prognost
risk
assess
develop
ip
includ
evalu
pulmonari
function
fev
dl
co
bal
fluid
inflammatori
mediat
level
genet
analys
singlenucleotid
polymorph
show
promis
identifi
patient
highest
risk
develop
ip
addit
use
establish
preclin
model
ip
result
robust
understand
mechan
contribut
inflamm
develop
ip
end
find
statement
support
shift
away
current
paradigm
noninfecti
lung
injuri
hsct
view
simpli
idiopath
clinic
syndrom
toward
process
lung
target
complex
cytotox
immunemedi
attack
solubl
inflammatori
mediat
like
tnfa
lp
reactiv
oxygen
speci
signific
albeit
exclus
contributor
ip
cell
lymphoid
myeloid
origin
play
direct
role
lung
injuri
occur
set
donorderiv
cellular
effector
may
also
recruit
lung
use
specif
receptorligand
interact
allow
travers
inflam
pulmonari
vascular
endothelium
parenchyma
contribut
epitheli
damag
dysfunct
donor
bone
marrowderiv
cell
epitheli
progenitor
stem
cell
multipot
differenti
capac
may
also
recruit
lung
hsct
role
cell
repair
injur
lung
transplant
current
subject
much
debat
anticip
review
hope
mechanist
insight
experiment
model
form
basi
translat
clinic
research
protocol
goal
treat
prevent
ip
hsct
understand
pathway
involv
develop
ip
improv
determin
patient
respond
best
new
agent
avail
therapeut
armamentarium
critic
improv
outcom
hsct
patient
author
disclosur
apm
report
grant
nih
paid
institut
support
work
report
manuscript
amgen
provid
kgf
experiment
studi
cite
within
manuscript
mg
report
receiv
payment
servic
third
parti
work
submit
paid
consult
relationship
novarti
vertex
institut
receiv
grant
dfg
bmbf
activ
outsid
submit
work
dkm
jab
iyh
rjf
report
receiv
payment
servic
third
parti
work
submit
relev
financi
activ
outsid
submit
work
krc
report
receiv
payment
servic
third
parti
work
submit
receiv
grant
athersi
support
amgen
studi
drug
central
pharmaci
support
activ
outsid
submit
work
note
disclosur
made
consist
intern
committe
medic
journal
editor
recommend
